Homeobox‑containing protein 1 loss is associated with clinicopathological performance in glioma

  • Authors:
    • Ping Zhang
    • Qinglin Liu
    • Shaofeng Yan
    • Guang Yuan
    • Jie Shen
    • Gang Li
  • View Affiliations

  • Published online on: July 21, 2017     https://doi.org/10.3892/mmr.2017.7050
  • Pages: 4101-4106
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Homeobox-containing protein 1 (HMBOX1) is a novel member of the homeobox family, and abnormal expression of HMBOX1 has been observed in several types of carcinoma. A total of 144 cases of confirmed glioma diagnoses were included in the present study. Grading was performed according to the World Health Organization (WHO) grading system for central nervous system neoplasm. Immunohistochemical staining of HMBOX1, proliferation marker protein Ki‑67 (Ki‑67) and microvessel density (MVD) was performed, and scores were calculated. HMBOX1 mRNA levels were detected using the reverse transcription quantitative polymerase chain reaction. It was identified that the expression of HMBOX1 was reduced in glioma tissue compared with normal brain tissue (P<0.05). The expression of HMBOX1 was downregulated significantly in WHO grade IV tumors compared with WHO grades II and III (P<0.05). HMBOX1 expression was significantly correlated with WHO grade, Karnofsky Performance Score, MVD and Ki‑67 expression; however, not associated with age or gender. Log‑rank testing did not demonstrate that HMBOX1 expression was associated with prognosis. In conclusion, HMBOX1 may be a potential diagnostic marker in glioma.

Related Articles

Journal Cover

October-2017
Volume 16 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang P, Liu Q, Yan S, Yuan G, Shen J and Li G: Homeobox‑containing protein 1 loss is associated with clinicopathological performance in glioma. Mol Med Rep 16: 4101-4106, 2017
APA
Zhang, P., Liu, Q., Yan, S., Yuan, G., Shen, J., & Li, G. (2017). Homeobox‑containing protein 1 loss is associated with clinicopathological performance in glioma. Molecular Medicine Reports, 16, 4101-4106. https://doi.org/10.3892/mmr.2017.7050
MLA
Zhang, P., Liu, Q., Yan, S., Yuan, G., Shen, J., Li, G."Homeobox‑containing protein 1 loss is associated with clinicopathological performance in glioma". Molecular Medicine Reports 16.4 (2017): 4101-4106.
Chicago
Zhang, P., Liu, Q., Yan, S., Yuan, G., Shen, J., Li, G."Homeobox‑containing protein 1 loss is associated with clinicopathological performance in glioma". Molecular Medicine Reports 16, no. 4 (2017): 4101-4106. https://doi.org/10.3892/mmr.2017.7050